Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.

Michael B. Atkins,Igor Puzanov,Elizabeth R. Plimack,Mayer Fishman,David F. McDermott,Daniel C. Cho,Ulka N. Vaishampayan,Saby George,Jamal Tarazi,William T. Duggan,Rodolfo F. Perini,Kathrine C. Fernandez,Toni K. Choueiri

Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.

2020

Michael B. Atkins
Igor Puzanov
Elizabeth R. Plimack
Mayer Fishman
David F. McDermott
Daniel C. Cho
Ulka N. Vaishampayan
Saby George
Jamal Tarazi
William T. Duggan
Rodolfo F. Perini
Kathrine C. Fernandez
Toni K. Choueiri

5080Background: Axitinib (AXI) plus pembrolizumab (pembro) showed superior overall survival (OS), progression-free survival (PFS) and response rate compared with sunitinib in a randomized Phase 3 t...

Keywords:

Oncology
Axitinib
Renal cell carcinoma
Pathology
in patient
Internal medicine
Pembrolizumab
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations